0001209191-20-052460.txt : 20200930
0001209191-20-052460.hdr.sgml : 20200930
20200930163758
ACCESSION NUMBER: 0001209191-20-052460
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200928
FILED AS OF DATE: 20200930
DATE AS OF CHANGE: 20200930
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nagendran Sukumar
CENTRAL INDEX KEY: 0001665124
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 201212657
MAIL ADDRESS:
STREET 1: C/O AVEXIS, INC., 2275 HALF DAY ROAD
STREET 2: SUITE 160
CITY: BANNOCKBURN
STATE: IL
ZIP: 60015
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7318 MORTON STREET
CITY: DALLAS
STATE: TX
ZIP: 75209
BUSINESS PHONE: 212.551.8702
MAIL ADDRESS:
STREET 1: 7318 MORTON STREET
CITY: DALLAS
STATE: TX
ZIP: 75209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-28
0
0001806310
Taysha Gene Therapies, Inc.
TSHA
0001665124
Nagendran Sukumar
C/O TAYSHA GENE THERAPIES, INC.
2280 INWOOD ROAD
DALLAS
TX
75235
1
0
0
0
Common Stock
2020-09-28
4
C
0
19226
A
19226
D
Series B Preferred Stock
2020-09-28
4
C
0
17647
0.00
D
Common Stock
19226
0
D
Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-1.0895 basis for no additional consideration, and had no expiration date.
/s/ Kamran Alam, Attorney-in-Fact
2020-09-30